These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 15878437)
1. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Kaya AD; Kiraz N Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704 [TBL] [Abstract][Full Text] [Related]
3. Voriconazole -- better chances for patients with invasive mycoses. Ghannoum MA; Kuhn DM Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915 [TBL] [Abstract][Full Text] [Related]
4. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723 [TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377 [TBL] [Abstract][Full Text] [Related]
7. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Guinea J; Peláez T; Alcalá L; Bouza E Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Guinea J; Peláez T; Alcalá L; Bouza E Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953 [TBL] [Abstract][Full Text] [Related]
9. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. Paterson PJ; Seaton S; Prentice HG; Kibbler CC J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236 [TBL] [Abstract][Full Text] [Related]
11. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates]. Oz Y; Akşit F; Kiraz N; Kiremitçi A Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574 [TBL] [Abstract][Full Text] [Related]
12. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. Singh J; Rimek D; Kappe R Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441 [TBL] [Abstract][Full Text] [Related]
13. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613 [TBL] [Abstract][Full Text] [Related]
14. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Chamilos G; Kontoyiannis DP Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654 [TBL] [Abstract][Full Text] [Related]
15. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093 [TBL] [Abstract][Full Text] [Related]
16. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. Meletiadis J; Mouton JW; Meis JF; Bouman BA; Donnelly PJ; Verweij PE; J Clin Microbiol; 2001 Dec; 39(12):4256-63. PubMed ID: 11724829 [TBL] [Abstract][Full Text] [Related]
17. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551 [TBL] [Abstract][Full Text] [Related]
18. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species. Misra R; Malik A; Singhal S Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890 [TBL] [Abstract][Full Text] [Related]
20. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. Espinel-Ingroff A; Johnson E; Hockey H; Troke P J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]